



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 19 Jun 2019 (#20)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

**Tygerberg Campus:** [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • **Stellenbosch Campus** [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)

## Important Notices & News

- NIH is expanding usage of **Notices of Special Interest** to announce interest in specific scientific research topics: [NOT-OD-19-107](#)
- Request for Information (RFI): Guidance on current clinical experience in the use of **Telemental Health for Suicide Prevention** in emergency department settings: [NOT-MH-19-030](#)

### 1. Clinical Studies of Mental Illness (Collaborative Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-19-297](#)

**Type:** R01

**Application Due Date:** [Standard dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) seeks to support collaborative clinical studies, not involving treatment development, efficacy, or effectiveness trials. Primary areas of focus include mental health genetics, biomarker studies, and studies of mental illnesses (e.g., psychopathology, neurodevelopmental trajectories of psychopathology) also when associated with HIV/AIDS. Applicants should apply to this FOA when two or more sites are needed to complete the study. Accordingly, the collaborating studies share a specific protocol across the sites and are organized as such in order to increase sample size, accelerate recruitment, or increase sample diversity and representation. In studies with a large number of sites, it is expected that one site will be submitted as a coordinating R01 for data management and/or other centralized administration. For a linked set of collaborative R01s, each application has its own Program Director/Principal Investigator (PD/PI). The collaborative R01 program provides a mechanism for cross-R01 coordination, quality control, database management, statistical analysis, and reporting.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

### 2. Non-Invasive Neurostimulation in Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD) (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-19-298](#)

**Type:** R01

**Application Due Date:** [Standard dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies using non-invasive neurostimulation/neuromodulation in the treatment of Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The goal of this FOA is to establish initial efficacy of neurostimulation/neuromodulation in the treatment of AD/ADRD or to refine these interventions for AD/ADRD patients. Multimodal or combination interventions are allowed, provided the focus and innovative component is neurostimulation. Applications that seek to develop devices, tools, or invasive techniques are outside the scope of this FOA.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

### 3. Aging, Driving and Early Detection of Dementia (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-AG-20-022](#)

**Type:** R01

**Application Due Date:** October 22, 2019. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) invites applications to conduct new research on automobile technology for signaling early signs of cognitive impairment in older drivers. Specifically, applications should propose research on using automobile technology coupled with other modes of assessing an individual's health and/or functional status to detect early signs of cognitive impairment. Two general kinds of research are envisioned: 1. Basic – intended to identify unobtrusive technology for monitoring driving performance and integrating it with other data to detect cognitive impairment, and 2. Methodological - intended to integrate driving-related data (and databases) with data on an individual's health and functional status to detect cognitive impairment.

**Budget:** NIA intends to commit \$3 million in FY 2020 to fund 4-6 awards. No more than \$500,000 in direct costs may be requested in any single year. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

### 4. Mechanistic Basis of Diffuse White Matter Disease in Vascular Contributions to Cognitive Impairment and Dementia (VCID)(Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-NS-19-039](#)

**Type:** R01

**Application Due Date:** August 14, 2019. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this funding opportunity announcement (FOA) is to support hypothesis-testing research to elucidate cellular and molecular mechanisms that underlie diffuse white matter disease and small vessel disease in the brain and how they may contribute to cognitive impairment and dementia.

**Budget:** NINDS intends to commit up to \$3,750,000 in FY 2020 to fund up to 6 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)

Research Development and Support Division (RDSD),  
Faculty of Medicine and Health Sciences, Stellenbosch University  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)  
Stellenbosch University  
2038 Wilcocks Building, Ryneveld Street  
Enquiries: *Lizél*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105